Abstract: The present disclosure is directed, in part, to pharmaceutical compositions comprising a Src protein tyrosine kinase inhibitor, an ATP citrate lyase (ACLY) inhibitor, and a PI3K inhibitor, and/or a Src and PIP2/PIP3 inhibitor of binding to ACLY, and a pharmaceutically acceptable carrier, methods of identifying a compound as a potential therapeutic agent for treating a disease or condition associated with the ACLY/Acetyl-CoA metabolic pathway in a cell, and methods of treating a disease or condition associated with the ACLY/Acetyl-CoA metabolic pathway.

Abstract: The invention provides methods for treating fibrosis, chronic inflammation, chronic pancreatitis, cancer or inflammatory myofibroblastic tumors (IMTs) in a subject in need thereof. The methods include providing a composition comprising a Lyn inhibitor and administering an effective amount of the composition to the subject to treat fibrosis, chronic inflammation, chronic pancreatitis, cancer or inflammatory myofibroblastic tumors (IMTs). fibrosis, chronic inflammation, chronic pancreatitis, cancer or inflammatory myofibroblastic tumors (IMTs).

Abstract: This invention pertains to the discovery that inhibition of phosphatidylinositol 3-kinase (PI3K) in human fetal undifferentiated cells induces morphological and functional endocrine differentiation. This is associated with an increase in MRNA levels of insulin, glucagon, and somatostatin, as well as an increase in the insulin protein content and secretion response to secretagogues. Blockade of PI3K also increases the proportion of pluripotent precursor cells coexpressing multiple hormones and the total number of terminally differentiated cells originating from these precursor cells. In one embodiment, this invention thus rpov9des methods for endocrine differentiation in cultured cells.